May 13, 2020
Stealth BioTherapeutics to Present at UBS Virtual Global Healthcare Conference
May 04, 2020
Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
Mar 30, 2020
Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020
Mar 03, 2020
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
Jan 08, 2020
Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
Dec 20, 2019
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
Dec 20, 2019
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
Nov 19, 2019
Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
Nov 11, 2019
Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
Oct 17, 2019
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
Oct 16, 2019
Mitochondrial Disease Therapies Market, 2019-2030
Oct 07, 2019
Mitochondrial Disease Therapies Market, 2019-2030
Oct 01, 2019
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
Sep 20, 2019
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
Sep 03, 2019
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
Jul 02, 2019
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
May 30, 2019
Stealth Biotherapeutics to Present at Upcoming Investor Conferences
Apr 25, 2019
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
Apr 02, 2019
Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Mar 19, 2019
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study